Bronze Diabetes: Evaluation and Management
Patients with bronze diabetes secondary to hereditary hemochromatosis require immediate initiation of weekly therapeutic phlebotomy to prevent progression of end-organ damage, though the diabetes itself is largely irreversible once established. 1
Understanding Bronze Diabetes
Bronze diabetes refers to the triad of skin hyperpigmentation, diabetes mellitus, and cirrhosis resulting from iron deposition in the pancreas, liver, and skin in hereditary hemochromatosis. 2 This represents advanced disease with established end-organ damage. 1
Initial Diagnostic Evaluation
Confirm Iron Overload and Genetic Diagnosis
- Measure serum ferritin and transferrin saturation as the initial biochemical assessment. 3
- Transferrin saturation >55% combined with ferritin >300 µg/L in men or >200 µg/L in women confirms significant iron overload. 3
- Perform HFE genetic testing after informed consent to confirm C282Y homozygosity (present in ~90% of cases) or C282Y/H63D compound heterozygosity. 3, 4
Assess for Cirrhosis and Hepatocellular Carcinoma Risk
- Liver biopsy is indicated when ferritin >1000 µg/L or liver enzymes are elevated to document cirrhosis and quantify hepatic iron concentration. 5, 6
- Documentation of cirrhosis is critical because it profoundly impacts prognosis—cirrhosis accounts for 75% of hemochromatosis-related deaths (30% from hepatocellular carcinoma, 20% from other cirrhotic complications). 1
- Survival in noncirrhotic patients equals the general population, while cirrhotic patients have significantly increased mortality even after adequate iron removal. 1
- Serum aminotransferases lack negative predictive value since half of cirrhotic patients have normal ALT/AST. 1
Evaluate Cardiac Complications
- Assess for cardiomyopathy and cardiac arrhythmias, which are the most common causes of sudden death in iron overload and may worsen during rapid iron mobilization. 1
- Cardiac complications are particularly dangerous during the initial phlebotomy phase. 5
Screen for Other End-Organ Damage
- Evaluate for hypogonadism (testicular iron deposition). 3
- Assess for arthropathy, particularly metacarpophalangeal joint involvement, which does not respond to phlebotomy. 1
Management Strategy
Therapeutic Phlebotomy Protocol
Initiate weekly or biweekly phlebotomy (500 mL blood removal) immediately as the cornerstone of treatment. 1, 5
Specific phlebotomy guidelines:
- Check hematocrit/hemoglobin before each phlebotomy; allow no more than 20% decline from baseline. 1, 5
- Monitor serum ferritin every 10-12 phlebotomies. 1, 5
- Target ferritin level of 50-100 µg/L as the therapeutic endpoint. 5, 6
- Once target is reached, continue maintenance phlebotomy at intervals to keep ferritin between 50-100 µg/L. 5, 6
Critical Precautions During Treatment
- Avoid vitamin C supplements entirely during phlebotomy, as pharmacologic vitamin C accelerates iron mobilization beyond transferrin's binding capacity, increasing pro-oxidant activity and risk of cardiac complications. 1, 5
- Patients receiving iron chelators should not exceed 200 mg daily vitamin C intake. 1
- Avoid raw shellfish due to risk of Vibrio vulnificus infection in iron-overloaded patients. 5
- No dietary iron restriction is necessary, as dietary modification affects only 2-4 mg/day versus 250 mg/week removed by phlebotomy. 5
Managing the Diabetes Component
The diabetes in bronze diabetes is largely irreversible and unresponsive to iron removal. 1 While phlebotomy may reduce insulin requirements in some patients, most show no improvement in glycemic control. 1, 7
- Manage diabetes with standard insulin therapy as the pancreatic β-cell damage from iron deposition is permanent. 7, 8
- The declining prevalence of diabetes in hemochromatosis (now 21.9% versus historical rates) reflects earlier diagnosis through genetic testing before irreversible pancreatic damage occurs. 7
Addressing Irreversible Manifestations
Certain features do not respond to phlebotomy:
- Arthropathy (most common irreversible complication). 1
- Hypogonadism. 1
- Established cirrhosis (though further progression may be slowed). 1
Features that may improve with phlebotomy:
- Malaise and fatigue. 1
- Skin pigmentation. 1
- Abdominal pain. 1
- Insulin requirements (in minority of patients). 1
Surveillance for Hepatocellular Carcinoma
- Cirrhotic patients require close HCC surveillance, though optimal screening intervals remain undefined. 1
- HCC is exceedingly rare in noncirrhotic patients, providing strong rationale for early intervention before cirrhosis develops. 1
- HCC risk persists even after adequate iron depletion in cirrhotic patients. 1
Consider Liver Transplantation
- Advanced decompensated cirrhosis is an indication for orthotopic liver transplantation evaluation. 5
- Current survival after transplantation is comparable to other liver disease etiologies when adequate iron removal occurs pre-transplant. 5
- Historical poor outcomes were related to perioperative cardiac and infectious complications from inadequate pre-transplant iron depletion. 5
Common Pitfalls to Avoid
- Do not delay phlebotomy while awaiting genetic confirmation if biochemical iron overload is documented—treatment prevents irreversible organ damage. 1
- Do not assume diabetes will improve with iron removal; most patients require ongoing insulin therapy. 1, 7
- Do not omit liver biopsy in patients with ferritin >1000 µg/L, as cirrhosis detection fundamentally changes prognosis and surveillance strategy. 5, 6
- Do not allow rapid iron mobilization in patients with cardiac involvement without close monitoring. 1, 5
Prognostic Implications
The presence of bronze diabetes indicates advanced disease with established cirrhosis and diabetes, both of which significantly reduce life expectancy. 1, 7 While phlebotomy prevents further progression and may improve some symptoms, the diabetes and cirrhosis represent largely irreversible damage. 1 This underscores the critical importance of family screening and early detection before symptomatic disease develops. 3, 4